-- 根据FactSet调查的分析师报告，Sensei Biotherapeutics (SNSE) 的平均评级为“买入”，平均目标价为50美元。 （报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）
Related Articles
Australia
BofA Adjusts Price Target on Pool to $226 From $229
Pool (POOL) has an average rating of overweight and mean price target of $262.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $228.70, Change: $+1.08, Percent Change: +0.47%
$POOL
Australia
BofA Adjusts Price Target on SiteOne Landscape Supply to $167 From $182
SiteOne Landscape Supply (SITE) has an average rating of overweight and mean price target of $169.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $142.26, Change: $-2.10, Percent Change: -1.45%
$SITE
Australia
Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility
Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%
$GILD$RCUS